PPARA and hypertriglyceridemia: Saroglitazar is a novel dual PPAR α/γ agonist with a predominant PPAR α agonistic activity that was approved in 2013 by the Drug Controller General of India (DCGI) for management of diabetic dyslipidemia and hypertriglyceridemia in T2DM patients not controlled by statins alone.